KBVH500 SARS-CoV-2 Neutralizing Antibodies Against Spike Mutation D614G ELISA Assay Kit

SARS-CoV-2 Neutralizing Antibodies Against Spike Mutation D614G ELISA Assay Kit

$1,445.00

The SARS-CoV-2 Neutralizing Antibodies against Spike Mutation D614G ELISA Assay Kit is used as an analytical tool for the qualitative detection all types of neutralizing antibodies against SARS-CoV-2 spike mutation D614G in serum or plasma. The Eagle Biosciences SARS-CoV-2 Neutralizing Antibodies against Spike Mutation D614G ELISA Assay Kit is for research use only and not to be used for diagnostic procedures.

SKU: KBVH500 Categories: , , , ,

SARS-CoV-2 Neutralizing Antibodies Against Spike Mutation D614G ELISA Assay Kit

The SARS-CoV-2 Neutralizing Antibodies Against Spike Mutation D614G ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Incubation Time: 3 hrs
Sample Type: Serum and plasma
Sample Size: 100 µL
Alternative Name: Coronavirus, SARS-CoV, Covid-19

Assay Principle

The method employs sandwich ELISA technique. The protein-protein interaction between HRP-D614G and hACE2 can be blocked by neutralizing antibodies against D614G. Samples and controls are pipetted in a blank microtitre plate and incubated with HRP conjugated human SARS-CoV-2 spike mutation D614G protein. The antibodies to SARS-CoV-2 spike mutation D614G present in the samples and controls bind to the SARS-CoV-2 spike mutation D614G protein to form a complex. This solution of bound and unbound antibodies to SARS-CoV-2 spike mutation D614G is then pipetted into human ACE2 coated microplate. After washing to remove the unbound complex and proteins, the substrate solution (TMB) is added to the microwells. Post incubation, color develops proportionally to the amount of Antibodies to SARS-CoV-2 (Covid-19) spike mutation D614G present in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Sample Preparation and Storage
Specimens should be clear and non-hemolyzed. Samples should be run at a number of dilutions to ensure accurate quantitation. Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. Samples should be diluted 1:1000 (v/v) for optimal recovery, (for example 1 ul sample + 999 ul sample diluent) prior to assay. In cases where matrix interferences is under or over observed, the samples may be diluted with Sample Diluent accordingly. The samples may be kept at 2 – 8°C for up to three days. For long-term storage please store at -20°C.
Note: Grossly hemolyzed samples are not suitable for use in this assay

Related Products

Mouse SARS-CoV-2 Spike RBD Antibody Quantitative ELISA
SARS-CoV-2 Spike Protein Antigen Quantitative ELISA
SARS-CoV-2 Spike RBD Antigen Quantitative ELISA

Additional Information

Assay Background

The SARS-CoV-2 (Covid-19) Neutralizing Antibodies against Spike Mutation D614G ELISA Assay Kits is used for assessing the specific biomarker in samples analytes which may be serum, plasma and cell culture supernatant as validated with the kit. The kit employs a blocking ELISA technique which mimics the virus neutralization process.
SARS-CoV-2-neutralizing antibodies primarily target the trimeric spike (S) glycoproteins on the viral surface that mediate entry into host cells. The S protein has two functional subunits that mediate cell attachment (the S1 subunit, existing of four core domains S1A through S1D) and fusion of the viral and cellular membrane (the S2 subunit).
Since the beginning of the COVID-19 pandemic in Wuhan, variants of the SARS-CoV-2 virus carrying a mutation in the spike protein at position 614 have largely replaced the original isolate. Established literatures have shown that the D614G mutation has a significant influence on the conformation of the trimeric spike. These structural changes in the G614 variant seem to enhance infectivity of virions through improved binding to the ACE2 receptor.
In addition, there are reports that antibodies generated against the Wuhan variant of SARS-CoV-2 may not fully protect against D614G.
We offer the Neutralizing Antibody Assay for the trimeric spike protein mutation D614G. This may help potential vaccine developers and others for comparative studies.
SARS-CoV-2 Neutralizing Antibodies Against Spike Mutation D614G ELISA

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations